Evaluation Of Dna Repair Biology Signatures To Predict Specific Carboplatin (C) Versus Docetaxel (D) Benefit In Advanced Triple-Negative Breast Cancer (Atnbc).

Holly Tovey,Joel S. Parker,Katherine A. Hoadley,Richard D. Kennedy,Orsolya Sipos,Lucy Kilburn,Sarah Kernaghan,Patrycja Gazinska,Syed Haider,Sarah E Pinder,Judith Bliss,Charles M. Perou,Anita Grigoriadis,Andrew Tutt,Maggie Chon U Cheang

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览53

暂无评分

摘要

1074Background: In the Triple Negative Trial we observed no improved response rate (RR) to C over D in aTNBC [Tutt et al, Nat Med 2018], but we did in BRCA1/2 mutated (mut) patients (pts). We hypot...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要